| US 7,566,442 B2 | ||
| Integrin targeted imaging agents | ||
| Gregory M. Lanza, St. Louis, Mo. (US); Samuel A. Wickline, St. Louis, Mo. (US); and Tom Harris, Salem, N.H. (US) | ||
| Assigned to Barnes-Jewish Hospital, St. Louis, Mo. (US); and Bristol Myers Squibb Medical Imaging, Inc., North Billerica, Mass. (US) | ||
| Filed on Jan. 09, 2008, as Appl. No. 11/971,818. | ||
| Application 11/305416 is a division of application No. 10/351463, filed on Jan. 24, 2003, granted, now 7,255,875. | ||
| Application 11/971818 is a continuation of application No. 11/305416, filed on Dec. 16, 2005, granted, now 7,344,698. | ||
| Claims priority of provisional application 60/351390, filed on Jan. 24, 2002. | ||
| Prior Publication US 2008/0175792 A1, Jul. 24, 2008 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 51/00 (2006.01); A61M 36/14 (2006.01) | ||
| U.S. Cl. 424—1.29 [424/1.11; 424/455; 424/9.3] | 13 Claims |
| 1. A composition comprising an emulsion of nanoparticles, wherein said nanoparticles consist of liquid perfluorocarbon cores
coated with lipid/surfactant, and
wherein said nanoparticles are coupled to a ligand specific for αvβ3, which comprises the formula
 and wherein the coupling of said nanoparticles to the ligand is through a covalent linkage, through a spacer, to a component
of the lipid/surfactant coating, and
wherein said nanoparticles incorporate at least one imaging agent.
|